GLP-1s, AI and the Informed Patient: Why Saudi Arabia Needs Continuous Care Now

Continuous care is the shift from one-off clinic visits to an ongoing, clinician-led relationship that supports patients between appointments. In Saudi Arabia, two forces now make it urgent: GLP-1 weight-loss and diabetes medicines, and AI tools that patients consult before they consult a doctor.

Patients no longer arrive at the clinic empty-handed. They bring an AI-generated shortlist of tests, a screenshot from a forum and, increasingly, a weight-loss injection they sourced themselves. The question for Saudi healthcare is not whether this informed patient is coming. It is who will guide them once they leave the consultation room.

EY's Global Consumer Health Survey 2026, which polled 7,500 consumers across ten markets including Saudi Arabia, puts numbers to the shift. Read alongside the Kingdom's chronic-disease burden and the rapid uptake of GLP-1 medicines, it points to one conclusion: care that ends at the appointment no longer matches how people manage their health.

What the data says, in brief

• AI now shapes clinical demand. 56% of consumers have requested, or would request, a test or prescription based on what an AI tool told them.
• Doctors still hold the trust. 89% call their doctor reliable, versus 68% for AI tools.
• Unguided access costs outcomes. GLP-1 users who sourced treatment informally reported negative outcomes from AI advice at 63%, against 38% for those prescribed by a professional.
• The data gap is real. 57% track their own health data; only 30% say their doctor uses it.
• The answer is continuity. The winning model moves from episodic visits to an always-on, clinician-led relationship.

Signal 1: AI in healthcare has joined the consultation, uninvited

AI has become a new referral source, and nobody is managing it. According to EY, 70% of consumers have acted, or would act, on search-engine information to request a test, treatment or prescription. For AI tools the figure is 56%, already ahead of social media at 45%.

AI is also substituting for care, not just preparing for it. Among people who delay seeing a professional, 41% turn to online search and 31% to AI tools instead. Nearly three in four expect routine tech-based self-diagnosis before any clinical visit within three to five years.

Yet trust has not moved. Doctors remain the most reliable source for 89% of respondents, ahead of AI (68%), search engines (61%) and social media (49%). Patients with chronic conditions lean on their doctors even more.

The implication: patients want AI's speed with a clinician's authority. Providers that put validated, clinician-governed digital guidance in front of patients will capture that demand. Those that don't will watch it flow to whichever chatbot answers first.

Signal 2: GLP-1s show what happens when access outruns support

GLP-1 medicines are the clearest stress test of the current care model. EY found that 58% of users obtained their prescription through a health professional. The rest came through weight-management programmes (23%), friends or family (20%) and fully online platforms (20%).

Saudi Arabia stands out positively: about two-thirds of Saudi respondents get their GLP-1 prescription from a doctor, compared with 37% in the UK. That professional anchor is an asset the Kingdom's providers can build on.

The outcome gap is the real story:

The pattern holds for safety too. Among those who sourced GLP-1s informally, 63% reported a negative outcome after acting on AI advice, versus 38% of those prescribed by a professional.

GLP-1 users are also far more digital. 60% rely on AI for health information, against 37% of non-users. Yet they are nearly twice as likely to report a negative outcome after acting on it (43% vs. 23%).

Independent real-world evidence points the same way. A JAMA Network Open cohort of 125,474 adults found that 64.8% of patients without type 2 diabetes and 46.5% of those with it stopped GLP-1 therapy within one year. Moderate or severe gastrointestinal side effects raised the risk of stopping, while greater weight loss lowered it (study summary).

The implication: a prescription is not a programme. Even on the professional pathway, four in ten users lapse. Dose titration, side-effect management, nutrition and adherence happen between visits, which is exactly where most systems go silent. For pharma, that gap is where Patient Support Programmes earn their value; for providers, it is where outcomes and loyalty are won or lost.

Signal 3: more patient data, less insight

Patients are generating health data at scale, and most of it never reaches a clinical decision. EY reports that 57% of consumers track their health data, yet only 30% say their doctor can access and actively use their wearable data. Respondents credit that same data with changing their exercise and lifestyle habits.

More data also brings more anxiety. Half of those who track their health feel overwhelmed by the information, against 39% of those who don't.

Comfort with AI follows a clear gradient. 65% are comfortable with AI handling administrative tasks such as booking appointments. That drops to 49% once AI moves into treatment decisions.

The implication: the value is not in collecting more data but in translating it. Patients need signals turned into clear next steps, and clinicians need summaries, not raw streams. AI should automate the operational layer, while clinical judgement stays visibly human.

What this means for healthcare in Saudi Arabia

The Kingdom is unusually well placed to lead the shift from episodic to continuous care, and has an unusually strong reason to.

Four conditions turn that burden into an opportunity.

1. Policy direction is already set. The Health Sector Transformation Program under Vision 2030 prioritises access, prevention and digitalisation. Strengthening prevention against health risks is one of its four strategic objectives.
2. Virtual care is proven at national scale. SEHA Virtual Hospital launched in February 2022 with 130 connected hospitals, including hospital-at-home follow-up for chronically ill patients.
3. Patients are digital-first. With near-universal internet access and a median age under 30, Saudi patients expect to manage services from their phones.
4. The professional anchor is strong. Two-thirds of Saudi GLP-1 users still go through a doctor, per EY. Providers hold the trust; they need tools to extend it beyond the visit.

The remaining barrier is execution. Speaking in the EY report, King Faisal Specialist Hospital's Chief Strategy and Transformation Officer, Noor Shabib, framed it plainly: the hard part is building digital solutions that serve the patient, rather than the organisation.

That is also a compliance question. Under the Personal Data Protection Law (PDPL), health data is sensitive personal data, and the law has been fully enforceable by SDAIA since 14 September 2024. Organisations that regularly process sensitive data must appoint a Data Protection Officer and meet strict cross-border transfer rules. Global consumer apps rarely start there.

From episodes to relationships: how CareSync puts the model to work

CareSync is a white-label, omnichannel continuous-care platform built in Saudi Arabia for hospitals, clinics and pharma Patient Support Programmes. It turns the three pillars EY sets out for a future-ready care model into daily practice.

Each EY pillar becomes a concrete capability, all resting on a compliant, provider-branded foundation.

Why white-label matters. The EY data is clear that patients trust their doctor first. CareSync keeps that trust where it already sits: the patient sees their hospital's brand, their clinician's name and their care team's messages, not a third-party app competing for attention.

Why it matters for pharma. A PSP delivered through the provider's own channel inherits the provider's credibility. Adherence support, titration guidance and adverse-event capture reach the patient inside a relationship they already trust, which is exactly where EY's data shows lapse rates fall.

A five-step playbook for providers and pharma

The shift is achievable within one planning cycle if leaders sequence it well.

1. Pick one high-stakes pathway first. Start where between-visit drop-off is costly and measurable: GLP-1 weight management, type 2 diabetes or a specialty therapy. Prove value narrowly before scaling.
2. Define the continuous journey. Map every touchpoint from prescription to month six: onboarding, titration, side-effect check-ins, lab reminders, refills. Assign each a channel and an owner.
3. Put AI on the operational layer. Automate booking, reminders, triage routing and data summaries, where comfort sits at 65%. Keep treatment decisions with clinicians, where comfort falls to 49%.
4. Connect the data the patient already generates. Bring wearable and self-reported data into one clinician view, filtered to what changes a decision. Close the 57%-to-30% gap.
5. Measure outcomes, not activity. Track persistence at 3 and 6 months, time to therapeutic dose, avoidable visits and patient-reported satisfaction. These are the numbers boards, payers and pharma partners will fund.

For pharma teams specifically: build support programmes into the prescriber relationship, not around it. The EY data suggests professional involvement lowers lapse rates, so PSPs that run through the treating provider's own channels are likely to retain patients longer and generate cleaner real-world evidence.

Frequently asked questions

How is AI changing patient behaviour in healthcare? Patients increasingly use AI tools to research symptoms and request specific tests or prescriptions. EY's 2026 survey found 56% have done so or would consider it, yet 89% still rate their doctor as the most reliable source.

Why do GLP-1 patients discontinue treatment? Common drivers include side effects, cost, supply and lack of ongoing support during dose titration. EY found discontinuation is lower when a healthcare professional is involved (41%) than through online (47%) or informal (49%) channels.

What is continuous care? Continuous care replaces isolated appointments with an ongoing, data-informed relationship between patient and care team. It combines digital check-ins, remote monitoring and timely clinical follow-up between visits.

How can Saudi hospitals launch digital patient engagement quickly? A white-label platform lets a hospital deploy a branded app and engagement journeys without building from scratch. It should meet PDPL and data-residency requirements and integrate with existing clinical workflows.

What should a pharma Patient Support Programme include in 2026? Onboarding, adherence and titration support, side-effect reporting with pharmacovigilance capture, and outcome tracking. It should run through the treating provider's channels to preserve clinical trust.

How common are obesity and diabetes in Saudi Arabia? GASTAT's 2024 health statistics classify 23.1% of Saudis aged 15+ as obese and 45.1% as overweight. The IDF Diabetes Atlas estimates 5.3 million adults lived with diabetes in 2024, and 43.6% of them were undiagnosed.

Does Saudi Arabia's PDPL apply to digital health platforms? Yes. Health data is sensitive personal data under the PDPL, which SDAIA has fully enforced since 14 September 2024. Platforms that regularly process it need a Data Protection Officer, a clear privacy policy and compliant data-transfer safeguards.

What is SEHA Virtual Hospital? SEHA Virtual Hospital is the Ministry of Health's virtual care network, launched in February 2022 with 130 connected hospitals. It offers specialist video consultations and hospital-at-home follow-up for chronically ill patients.

The appointment is no longer the product

The informed patient is not a threat to the clinician. They are a patient asking for more of the clinician, more often, in the channels they already use. GLP-1s have simply made that demand impossible to ignore.

The organisations that win the next decade of Saudi healthcare will not be those with the most beds or the smartest chatbot. They will be the ones that turn trust into a continuous relationship.

Ready to extend your care beyond the visit? Book a CareSync demo at care-sync.co to see how a branded, PDPL-ready continuous care platform can launch on your first pathway.

About CareSync

This article was prepared by the CareSync Team, drawing on experience across pharma, medical affairs, market access and digital health in Saudi Arabia. CareSync is a white-label continuous-care platform built in Riyadh for hospitals, clinics and pharma Patient Support Programmes.

Sources

1. Dalla Torre, K. How GLP-1s and AI are changing the way consumers interact with healthcare. EY Global Consumer Health Survey 2026, 10 June 2026.
2. Rodriguez, P.J. et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open, 2025;8(1):e2457349. Author summary.
3. General Authority for Statistics (GASTAT), Health Determinants Statistics 2024, as reported by Gulf News, 19 November 2024.
4. International Diabetes Federation. IDF Diabetes Atlas: Saudi Arabia country report 2000–2050.
5. Saudi Vision 2030. Health Sector Transformation Program.
6. Ministry of Health. Health Sector Transformation Goals.
7. Arab News. Saudi Arabia launches first virtual hospital, 28 February 2022.
8. Clyde & Co. Saudi Arabia's Personal Data Protection Law becomes enforceable, 10 September 2024.
9. DataReportal (Kepios). Digital 2025: Saudi Arabia, 3 March 2025.